ClinicalTrials.gg
CompletedNCT01835470Updated Feb 26, 2021Results posted

Efficacy, Safety, Pharmacokinetics and Immunogenicity Study of Abatacept Administered Intravenously to Treat Active Polyarticular-course Juvenile Idiopathic Arthritis in Japan

A Phase 3 interventional study of Abatacept in Juvenile Idiopathic Arthritis, sponsored by Bristol-Myers Squibb. Completed at 13 sites in Japan. Open to participants aged 4 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-02-26.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
4 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Arthritis, Juvenile with a site in Japan — 3 open to participants now, 6 under way, 5 of them phase 3. Arthritis, Juvenile · Japan.

Enrollment
9th of 11
23 · median 58
Started
2013
the only one that year
Phase 3
10 of 12
3 open now
Registered
3rd of 12
by date
Lead sponsor
1 of 12
Bristol-Myers Squibb

Among the 12 studies in Arthritis, Juvenile with a site in Japan, this one is the 9th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2013, is one of 10 in phase 3, and was the 3rd registered.

Arthritis, Juvenile

366 studies on the registry are indexed under Arthritis, Juvenile; 102 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

3 of the 12 studies in Arthritis, Juvenile with a site in Japan are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.

This study: 4 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Arthritis, Juvenile with a site in Japan, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy of Abatacept after intravenous administration in Japanese children and adolescents with active juvenile idiopathic arthritis who have a history of an inadequate response or intolerance to Methotrexate or biologics

03

Conditions studied

  • Juvenile Idiopathic Arthritis

Browse trials for

04

Who can participate

Ages eligible
4 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who have a history of an inadequate therapeutic response or intolerance in the opinion of the examining physician to at least one biologics or Methotrexate (MTX).
  • Diagnosis of Juvenile Idiopathic Arthritis (JIA) by International League of Associations for Rheumatology (ILAR) criteria as oligoarticular, polyarticular Rheumatoid Factor (RF+), polyarticular (RF-), or systemic with a polyarticular-course.
  • Men and women, ages 4 to 17 years, inclusive at enrollment.
  • Subjects must have a history of at least 5 joints with active disease and must have currently active articular disease as defined by:

    1. ≥2 active joints (e.g. presence of swelling, or if no swelling is present, limitation of motion (LOM) accompanied by pain, tenderness, or both) at screening and at Week 0 (Day 1).
    2. ≥2 joints with LOM at screening and at Week 0 (Day 1).

Exclusion criteria

Exclusion Criteria:

  • Systemic onset JIA with any of the following manifestations within the last 6 months prior to enrollment: intermittent fever due to JIA, rheumatoid rash, hepatosplenomegaly, pleuritis, pericarditis, or macrophage activation syndrome.
  • Presence of any other rheumatic disease or major chronic infectious/inflammatory/immunologic disease (e.g. inflammatory bowel disease, psoriatic arthritis, spondyloarthropathy, hypogammaglobulinemia, or systemic lupus erythematosus, etc.)
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Abatacept

    Abatacept 10 mg/kg (for body weight less than 75 kg), 750 mg (for body weight between 75 and 100 kg), and 1g (for body weight above 100kg) intravenous infusion on Week 0 (Day 1), Week 2 (Day 15), Week 4 (Day 29) and every 4 weeks (28 days) thereafter up to the end of the study

    Drug: Abatacept

Interventions

  • Also known as: BMS-188667, ONO-4164

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Experiencing a American College of Rheumatology (ACR) Pediatric 30 Response at Week 16

    American College of Rheumatology (ACR) pediatric (PED) 30 response was defined as '≥30% improvement' and '≥3 of the 6 Juvenile Idiopathic Arthritis (JIA) core set' and ≥30% worsening in not more than 1 of the 6 JIA core set variables. JIA core set variables defined as the number of active joints, number of joints with Limit of Motion (LOM), physician's global assessment of disease severity, patient global assessment of overall well being, parent assessment of physical function, and acute phase reactant value. A non-responder imputation was applied.

    Time frame: Week 16 (Day 113)

Secondary outcomes

  1. Percentage of Participants Experiencing a American College of Rheumatology Pediatric 50, 70, 90 Response or Inactive Disease at Week 16

    ACR PED 50 response is defined as '≥50% improvement' and '≥3 of the 6 Juvenile Idiopathic Arthritis (JIA) core set' and ≥30% worsening in not more than 1 of the 6 JIA core set variables. ACR PED 70 response is defined as '≥70% improvement' and '≥3 of the 6 JIA core set' and ≥30% worsening in not more than 1 of the 6 JIA core set variables. ACR PED 90 response is defined as '≥90% improvement' and '≥3 of the 6 JIA core set' and ≥30% worsening in not more than 1 of the 6 JIA core set variables. Inactive disease status is defined as no active joints, physician's global assessment of disease severity equal or less than 10mm and C-reactive protein (CRP) within normal limits (0.3 mg/dL). A non-responder imputation is applied. mm=millimeter; mg/dL=milligrams/deciliter

    Time frame: Week 16 (Day 113)

  2. Median Percentage of Improvement From Baseline in Physical Function as Assessed by the Childhood Health Assessment Questionnaire (CHAQ) Disability Index at Week 16

    Physical function was evaluated using the disability section of the Childhood Health Assessment Questionnaire (CHAQ). The questionnaire was derived from the adult HAQ. The disability section assessed physical functions in 8 domains: dressing and grooming, arising, eating, walking, hygiene, reach, grip and common activities. The questions were evaluated on a 4-point scale: 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty and 3 =unable to do. Higher scores indicate greater dysfunction. A disability index was calculated as the mean of the 8 functional scales. The percentage of Improvement from baseline was calculated using the following equation: (Baseline value - Post-baseline value) / Baseline value x 100.

    Time frame: Week 16 (Day 113)

  3. Number of Participants With Death, Serious Adverse Events (SAEs), Drug-Related SAEs, Discontinuation Due to Drug-Related SAEs, Drug-Related Adverse Events (AEs), and Discontinuation Due to Drug-Related AEs During the Short Term Period

    AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. SAEs also include hospitalizations for elective surgical procedures. Drug-related=related or missing relationship to study drug. Data includes all events from the date of the first dose of the study drug up to 56 days post the last dose of the study drug in the short-term period or start of the long-term period, whichever occurred first.

    Time frame: Day 1 up to 56 days post Week 16 (Day 113); approximately 6 months

  4. Maximum Observed Concentration (Cmax) of Abatacept During the Short Term Period

    Cmax was obtained from the serum concentration versus time data after intravenous administration of abatacept. Blood samples were collected at 0 hour (pre-dose) on Days 15 and 29 and at 0 hour (pre-dose) and 0.5 hours (post dose) on Days 57, 85, and 113. A blood sample was also collected on an interim visit that occurred on any day between Day 92 and Day 110. ug/mL=micrograms/milliliter

    Time frame: 9 time points up to Week 16 (Day 113)

  5. Trough Observed Concentration (Ctrough) of Abatacept During the Short Term Period

    Blood samples were collected at 0 hour (pre-dose) on Days 15 and 29 and at 0 hour (pre-dose) and 0.5 hours (post dose) on Days 57, 85, and 113. A blood sample was also collected on an interim visit that occurred on any day between Day 92 and Day 110. ug/mL=micrograms/milliliter

    Time frame: 9 time points up to Week 16 (Day 113)

  6. Number of Participants With Positive Immunogenicity During the Short Term Period

    A positive immunogenicity response for 'Cytotoxic T-lymphocyte antigen (CTLA4), Immunoglobulin (Ig)', 'Ig and/or Junction Region', respectively = (1) missing baseline immunogenicity measurement and positive analytical laboratory reported immunogenicity response post-baseline (2) negative baseline immunogenicity response and positive analytical laboratory reported immunogenicity response post-baseline (3) positive baseline immunogenicity response and positive analytical laboratory reported immunogenicity response post-baseline with titer value strictly greater than the baseline titer value. Assessment based on assay cutpoint value. Serum samples were collected prior to study medication at Week 0 (Day 1), Week 8 (Day 57), and Week 16 (Day 113) in the short term period. Participants who early discontinued from the study or complete and did not switch to commercial abatacept had a serum sample collected on final visit or early termination visit, 28, 84 and 168 days after the last dose.

    Time frame: Day 1 up to Week 16 (Day 113)

07

Results

Posted Jan 11, 2017

Participant flow

23 participants were enrolled and 20 participants were treated. Reason for non-treatment was that 3 participants no longer met study criteria.

Short Term Treatment Period (to Week 16)
Participant flow — Short Term Treatment Period (to Week 16)
MilestoneAbatacept
Started20
Completed20
Not completed0
Long Term Treatment Period
Participant flow — Long Term Treatment Period
MilestoneAbatacept
Started20
Completed16
Not completed4
Withdrew: Subject request to discontinue1
Withdrew: Lack of efficacy3

Outcome measures

PrimaryPercentage of Participants Experiencing a American College of Rheumatology (ACR) Pediatric 30 Response at Week 16

American College of Rheumatology (ACR) pediatric (PED) 30 response was defined as '≥30% improvement' and '≥3 of the 6 Juvenile Idiopathic Arthritis (JIA) core set' and ≥30% worsening in not more than 1 of the 6 JIA core set variables. JIA core set variables defined as the number of active joints, number of joints with Limit of Motion (LOM), physician's global assessment of disease severity, patient global assessment of overall well being, parent assessment of physical function, and acute phase reactant value. A non-responder imputation was applied.

Time frame:
Week 16 (Day 113)
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing a American College of Rheumatology (ACR) Pediatric 30 Response at Week 16
percentage of participantsAbatacept
Percentage of Participants Experiencing a American College of Rheumatology (ACR) Pediatric 30 Response at Week 1690.0 (68.3 to 98.8)
SecondaryPercentage of Participants Experiencing a American College of Rheumatology Pediatric 50, 70, 90 Response or Inactive Disease at Week 16

ACR PED 50 response is defined as '≥50% improvement' and '≥3 of the 6 Juvenile Idiopathic Arthritis (JIA) core set' and ≥30% worsening in not more than 1 of the 6 JIA core set variables. ACR PED 70 response is defined as '≥70% improvement' and '≥3 of the 6 JIA core set' and ≥30% worsening in not more than 1 of the 6 JIA core set variables. ACR PED 90 response is defined as '≥90% improvement' and '≥3 of the 6 JIA core set' and ≥30% worsening in not more than 1 of the 6 JIA core set variables. Inactive disease status is defined as no active joints, physician's global assessment of disease severity equal or less than 10mm and C-reactive protein (CRP) within normal limits (0.3 mg/dL). A non-responder imputation is applied. mm=millimeter; mg/dL=milligrams/deciliter

Time frame:
Week 16 (Day 113)
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing a American College of Rheumatology Pediatric 50, 70, 90 Response or Inactive Disease at Week 16
percentage of participantsAbatacept
ACR PED 5075.0 (50.9 to 91.3)
ACR PED 7070.0 (45.7 to 88.1)
ACR PED 9035.0 (15.4 to 59.2)
Inactive Disease25.0 (8.7 to 49.1)
SecondaryMedian Percentage of Improvement From Baseline in Physical Function as Assessed by the Childhood Health Assessment Questionnaire (CHAQ) Disability Index at Week 16

Physical function was evaluated using the disability section of the Childhood Health Assessment Questionnaire (CHAQ). The questionnaire was derived from the adult HAQ. The disability section assessed physical functions in 8 domains: dressing and grooming, arising, eating, walking, hygiene, reach, grip and common activities. The questions were evaluated on a 4-point scale: 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty and 3 =unable to do. Higher scores indicate greater dysfunction. A disability index was calculated as the mean of the 8 functional scales. The percentage of Improvement from baseline was calculated using the following equation: (Baseline value - Post-baseline value) / Baseline value x 100.

Time frame:
Week 16 (Day 113)
Reported as:
Median · percentage of improvement from baseline
Median Percentage of Improvement From Baseline in Physical Function as Assessed by the Childhood Health Assessment Questionnaire (CHAQ) Disability Index at Week 16
percentage of improvement from baselineAbatacept
Median Percentage of Improvement From Baseline in Physical Function as Assessed by the Childhood Health Assessment Questionnaire (CHAQ) Disability Index at Week 1643.18 (0.00 to 100.00)
SecondaryNumber of Participants With Death, Serious Adverse Events (SAEs), Drug-Related SAEs, Discontinuation Due to Drug-Related SAEs, Drug-Related Adverse Events (AEs), and Discontinuation Due to Drug-Related AEs During the Short Term Period

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. SAEs also include hospitalizations for elective surgical procedures. Drug-related=related or missing relationship to study drug. Data includes all events from the date of the first dose of the study drug up to 56 days post the last dose of the study drug in the short-term period or start of the long-term period, whichever occurred first.

Time frame:
Day 1 up to 56 days post Week 16 (Day 113); approximately 6 months
Reported as:
Number · participants
Number of Participants With Death, Serious Adverse Events (SAEs), Drug-Related SAEs, Discontinuation Due to Drug-Related SAEs, Drug-Related Adverse Events (AEs), and Discontinuation Due to Drug-Related AEs During the Short Term Period
participantsAbatacept
Death0
SAEs2
Drug-Related SAEs1
Discontinuation Due to Drug-Related SAEs0
Drug-Related AEs5
Discontinuation Due to Drug-Related AEs0
SecondaryMaximum Observed Concentration (Cmax) of Abatacept During the Short Term Period

Cmax was obtained from the serum concentration versus time data after intravenous administration of abatacept. Blood samples were collected at 0 hour (pre-dose) on Days 15 and 29 and at 0 hour (pre-dose) and 0.5 hours (post dose) on Days 57, 85, and 113. A blood sample was also collected on an interim visit that occurred on any day between Day 92 and Day 110. ug/mL=micrograms/milliliter

Time frame:
9 time points up to Week 16 (Day 113)
Reported as:
Geometric mean · ug/mL
Maximum Observed Concentration (Cmax) of Abatacept During the Short Term Period
ug/mLAbatacept
Day 57163.13 ± 26.22
Day 85172.43 ± 23.15
Day 113167.85 ± 18.42
SecondaryTrough Observed Concentration (Ctrough) of Abatacept During the Short Term Period

Blood samples were collected at 0 hour (pre-dose) on Days 15 and 29 and at 0 hour (pre-dose) and 0.5 hours (post dose) on Days 57, 85, and 113. A blood sample was also collected on an interim visit that occurred on any day between Day 92 and Day 110. ug/mL=micrograms/milliliter

Time frame:
9 time points up to Week 16 (Day 113)
Reported as:
Geometric mean · ug/mL
Trough Observed Concentration (Ctrough) of Abatacept During the Short Term Period
ug/mLAbatacept
Day 1525.50 ± 27.61
Day 2938.64 ± 29.08
Day 5717.24 ± 36.63
Day 8516.79 ± 40.01
Day 11315.56 ± 36.61
SecondaryNumber of Participants With Positive Immunogenicity During the Short Term Period

A positive immunogenicity response for 'Cytotoxic T-lymphocyte antigen (CTLA4), Immunoglobulin (Ig)', 'Ig and/or Junction Region', respectively = (1) missing baseline immunogenicity measurement and positive analytical laboratory reported immunogenicity response post-baseline (2) negative baseline immunogenicity response and positive analytical laboratory reported immunogenicity response post-baseline (3) positive baseline immunogenicity response and positive analytical laboratory reported immunogenicity response post-baseline with titer value strictly greater than the baseline titer value. Assessment based on assay cutpoint value. Serum samples were collected prior to study medication at Week 0 (Day 1), Week 8 (Day 57), and Week 16 (Day 113) in the short term period. Participants who early discontinued from the study or complete and did not switch to commercial abatacept had a serum sample collected on final visit or early termination visit, 28, 84 and 168 days after the last dose.

Time frame:
Day 1 up to Week 16 (Day 113)
Reported as:
Number · participants
Number of Participants With Positive Immunogenicity During the Short Term Period
participantsAbatacept
Number of Participants With Positive Immunogenicity During the Short Term Period0

Adverse events

Collected over During the cumulative period which is from the first dose date up to 56 days beyond the last dose of study medication in the LT period for participants entering the LT or up to 56 days beyond the last dose of study medication in the ST period for participants not entering the LT period. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IV ABATACEPT—6/20 (30%)20/20 (100%)
Most frequent serious events
Most frequent serious events
EventIV ABATACEPT
JUVENILE IDIOPATHIC ARTHRITISMusculoskeletal and connective tissue disorders2/20
ENTEROCOLITIS VIRALInfections and infestations1/20
GASTROENTERITISInfections and infestations1/20
VARICELLAInfections and infestations1/20
VIRAL TONSILLITISInfections and infestations1/20
LOWER LIMB FRACTUREInjury, poisoning and procedural complications1/20
Most frequent other events
Showing 10 of 47
Most frequent other events
EventIV ABATACEPT
NASOPHARYNGITISInfections and infestations17/20
PHARYNGITISInfections and infestations12/20
INFLUENZAInfections and infestations10/20
STOMATITISGastrointestinal disorders7/20
LIGAMENT SPRAINInjury, poisoning and procedural complications7/20
HEADACHENervous system disorders7/20
CONTUSIONInjury, poisoning and procedural complications6/20
UPPER RESPIRATORY TRACT INFLAMMATIONRespiratory, thoracic and mediastinal disorders6/20
DIARRHOEAGastrointestinal disorders5/20
SEASONAL ALLERGYImmune system disorders5/20

Baseline characteristics

All Treated Participants: All participants who received at least one dose of study medication

Age, Categorical
Age, Categorical(Participants)Abatacept
<=18 years20
Between 18 and 65 years0
>=65 years0
Age, Continuous
Age, Continuous(years)Abatacept
Mean10.2 ± 3.24
Sex: Female, Male
Sex: Female, Male(Participants)Abatacept
Female15
Male5
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Abatacept
Japanese20
Region of Enrollment
Region of Enrollment(Participants)Abatacept
Japan20
08

Study locations

13 sites
  • Local Institution
    Oobu-shi, Aichi 4748710, Japan
  • Local Institution
    Sapporo-shi, Hokkaido 0048618, Japan
  • Local Institution
    Sapporo-shi, Hokkaido 0608648, Japan
  • Local Institution
    Kobe, Hyogo 6500047, Japan
  • Local Institution
    Kagoshima-shi, Kagoshima 8908520, Japan
  • Local Institution
    Yokohama-shi, Kanagawa 2328555, Japan
  • Local Institution
    Yokohama-shi, Kanagawa 2360004, Japan
  • Local Institution
    Sendai-shi, Miyagi 9893126, Japan
  • Local Institution
    Niigata-shi, Niigata 9518520, Japan
  • Local Institution
    Nakagami-gun, Okinawa 9030215, Japan
  • Local Institution
    Takatsuki-shi, Osaka 5698686, Japan
  • Local Institution
    Bunkyo-ku, Tokyo 1138603, Japan
  • Local Institution
    Shinjuku-ku, Tokyo 1620054, Japan
09

References and documents

Publications

  • Hara R, Umebayashi H, Takei S, Okamoto N, Iwata N, Yamasaki Y, Nakagishi Y, Kizawa T, Kobayashi I, Imagawa T, Kinjo N, Amano N, Takahashi Y, Mori M, Itoh Y, Yokota S. Intravenous abatacept in Japanese patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study. Pediatr Rheumatol Online J. 2019 Apr 30;17(1):17. doi: 10.1186/s12969-019-0319-4. PubMed 31039807 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2013 to primary completion in Nov 2015, 27 months.

Results were first posted in Jan 2017, 1 year 1 month after primary completion.

Of 36 phase 3 interventional studies under Arthritis, Juvenile, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's 27 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2013
First posted
Apr 19, 2013
StartActual
Aug 9, 2013
Primary completionActual
Nov 24, 2015
CompletionActual
Jul 30, 2018
Results first posted
Jan 11, 2017
Last update
Feb 26, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01835470
Responsible party
Sponsor
First posted
Apr 19, 2013
Start date
Aug 9, 2013
Primary completion
Nov 24, 2015
Completion
Jul 30, 2018
Results posted
Jan 11, 2017
Last update
Feb 26, 2021

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abatacept

Start the discussion